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ABSTRACT 
Conservative treatment for invasive bladder cancer (BC) involves a complete 
transurethral tumor resection combined with chemotherapy (CT) and radiotherapy 
(RT). The major obstacles of chemo-radiotherapy are the addition of the toxicities 
of RT and CT, and the recurrence due to RT and CT resistances. The flavonoid 
Silybin (Sb) inhibits pathways involved in cell survival and resistance mechanisms, 
therefore the purpose of this paper was to study in vitro and in vivo, the ability of 
Sb to improve the response to RT, in two murine BC cell lines, with different levels 
of invasiveness, placing emphasis on radio-sensitivity and pathways involved in 
radio-resistance and survival. In vitro, Sb radio-sensitized murine invasive cells 
through the inhibition of RT-induced NF-κB and PI3K pathways, and the increase 
of oxidative stress, while non-invasive cells did not show to be sensitized. In vivo, 
Sb improved RT-response and overall survival in invasive murine tumors. Since Sb 
is already being tested in clinical trials for other urological cancers and it 
improves RT-response in invasive BC, these results could have 
translational relevance, supporting further research. This article is protected by 
copyright. All rights reserved
Keywords: bladder cancer; bladder preservation; Silybin; radiotherapy; 
radiosensitizer. 
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LIST OF ABBREVIATIONS 
BC = Bladder Cancer 
CT = Chemotherapy 
RT = Radiotherapy 
Sb = Silybin 
NF-κB = Nuclear transcription Factor kappa B 
RSF = Radiosensitizing Factor 
DEF = Dose Enhancement Factor 
ROS = Reactive Oxygen Species 
INTRODUCTION 
Bladder cancer (BC) ranks second as a cause of death from genitourinary cancer 
in men. Transitional bladder tumors are the most frequent type of BC. Although 
most patients present non-invasive disease, 10-20% eventually progress to 
muscle-invasive disease. In addition about one-third of the new cases are muscle-
invasive when diagnosed [Jemal et al., 2010]. 
Radical cystectomy is the gold standard treatment for patients with invasive BC 
[Hautmann et al., 2006; Stein et al., 2001]. However, it is associated with high 
complication rates and compromises the quality of the patient’s life[Konety et al., 
2006; Manoharan et al., 2009]. The main treatment for bladder preservation 
includes complete transurethral tumor resections combined with chemotherapy 
(CT) and radiotherapy (RT)[Caffo et al., 2013]. While chemo-radiotherapy 
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addition of the toxicities of RT and CT, and the recurrence due to RT or CT 
resistances. It is then important to study new molecular targets to optimize the 
conservative treatment [Caffo et al., 2013]. 
Nuclear transcription factor kappa B (NF-κB) regulates several genes involved in 
tumor development, progression and treatment resistance in a wide range of 
tumors. Among others, NF-κB overexpression has been proposed as a predictor of 
radio-resistance and a potential target to overcome resistance in muscle-invasive 
BC[Ahmed and Li, 2008; Koga et al., 2011].  
Silybin (Sb) [(2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-
2- (hydroxy-methyl)-2,3-dihydrobenzo[b][1,4]doxin-6-yl] chroman-4-one] is a 
flavonoid and the main compound of silymarin, the extract obtained from the milk 
thistle (Silybum marianum)[Kvasnicka et al., 2003]. Sb has clearly demonstrated 
inhibition of multiple cancer cell features including growth, angiogenesis, multi-drug 
resistance, invasion and metastasis[Gazak et al., 2007; Ramasamy and Agarwal, 
2008; Singh and Agarwal, 2005]. Sb mechanisms of action include regulation of 
transcription factors including NF-κB, cell cycle regulatory and apoptotic signaling 
pathways[Li et al., 2010]. Sb also possesses anti-inflammatory and antioxidative 
properties[Kim et al., 2013; Kren and Walterova, 2005]. Furthermore, in previous 
works, we found that Sb inhibited BC cell growth and enhanced the effects of 
photodynamic therapy [Gandara et al., 2014]. 
The aim of this work was to study in vitro and in vivo, the ability of Sb to improve 
the response to RT, in two murine BC cell lines, with different levels of 
invasiveness [Lodillinsky et al., 2009], making emphasis on radio-sensitivity and 
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MATERIALS AND METHODS 
Cell culture:Murine non-invasive MB49 was gently donated by the Tomas 
Jefferson University (Philadelphia) and invasive MB49-I, was derived from 
MB49 as described in [Lodillinsky et al., 2009]. Both cell lines were cultured in 
RPMI-1640 from Gibco (31800-014;USA) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS) from Internegocios S.A. (Argentina) and 80 µg/ml 
gentamycin, at 37ºC in a humidified atmosphere of 5% CO2. 
 
Silybin and irradiation: Sb (C25H22O10 ≥98% purity) from Sigma-Aldrich (USA). 
Stock solution was prepared in Dimethylsufoxide (DMSO; Protide-Pharmaceutical) 
for in vitro and in vivoassays. Cells and tumors were irradiated using a Theratron 
780 with 60Co source gamma-radiation emitter (dose rate: 1 Gy/minute). Sb 
treatments or DMSO as a control, were performed in RPMI with 2% of FBS. 
 
Cell viability: Cytotoxic effects of Sb, +/-RT treatment,were analyzed using MTS-
assay (Promega; USA) in a Multiskan Ascent (Labsystem) at 492nm/620nm. To 
determine Sb inhibitory dose 50% (ID50), 8x103 cells were cultured in 96-well plates 
and treated with Sb (0.01, 0.1, 1, 10, 20, 40, 60, 80, 100 and 150 µM) for 24 hours. 
To assess the cytotoxic effect of the combined treatment (Sb+RT), 1x103 cells 
were cultured in 96-well plates and viability was measured 5 days after RT (0, 2, 4 
and 6 Gy). Radio-sensitivity factors (RSF) were calculated by RSF= optical density 
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Colony formationassay: To analyze radio-sensitivity to Sb, 500-1500 MB49 or 
MB49-I cells were cultured in triplicate in 6-well plates, treated +/-Sb (60 µM) for 
24 hours and then irradiated (0, 2, 4 and 6 Gy). After RT, medium was changed 
maintaining Sb treatment but supplementing with 10% FBS, and plates were 
incubated for 10-14 days until cell colonies were visible to the naked eye, adapted 
from [Nambiar et al., 2015]. Colonies were fixed with methanol/acetic acid(3:1), 
stained with Giemsa and those with more than 50 cells were registered to calculate 
plating efficiency (PE) and surviving fractions (SF), as previously[Franken et al., 
2006]. PE= mean colony number/cells plated; and SF= sample PE/PE of its non-
irradiated control. Dose enhancement factors (DEF) were calculated asDEF= dose 
with RT-only/ dose with RT and Sb, for a same biological effect. 
 
Cell cycle assay: cell cycle was analyzed using DNA content measurement with 
Propidium Iodide (PI). Sub-confluent monolayers were treated +/-Sb (60 µM) for 24 
hours. Attached and detached cells were harvested, suspended in 0.5 ml of PBS 
with minimal cell aggregation and fixed with 4.5 ml of 70% ethanol on ice. The cell 
suspension was centrifuged and cells were suspended and incubated with PI 
(0.1% (v/v) Triton X-100, 50 µg/mL PI and 100 µg/mL DNase-free RNase A) in 
PBS for 30 minutes at room temperature. 20,000 cells were identified on a Partec-
Cyflow flow cytometer and analyzed using Cyflogic V.1.2.1. 
 
Gene reporter assay: cells were transiently transfected with a plasmid carrying 
the luciferase gene under control of NF-κB-response element, as previously 
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Luciferase® Reporter–Assay-System (Promega; USA) in a Triathler luminometer 
liquid scintillation counter (Hidex, Turku, Finland) and normalized to constitutive 
renilla activity. 
 
Immunoblot: proteins (80 µg) from whole-cell or nuclear extracts were 
electrophoresed on SDS–PAGE and transferred to PVDF membranes. Antibodies: 
NF-κB-p65 protein (Santa Cruz Biotechnology, sc-109, USA), survivin (Cell-
Signaling 2802, USA), pAkt (Santa Cruz Biotechnology,sc-7985-R, USA), Akt 
(Santa Cruz Biotechnology,sc-8312, USA),caspase-3 (Cell-Signaling 9662S, 
USA) and PARP (Cell-Signaling 9532S, USA). Densitometry units were referred 
to β-actin (Sigma A5441, USA). 
Sub-confluent monolayers were treated +/-Sb (60 µM) for 24 hours, +/-RT (8 Gy). 
To assess NF-κB nuclear translocation, nuclear extracts were obtained 30-60 
minutes after RT using the NE-PER™ Nuclear and Cytoplasmic Extraction 
Reagents (Thermo ScientificTM 78833, USA) according to manufacturer's 
instructions. Survivin, Akt, p-Akt and procaspase-3 were evaluated in whole-cell 
extracts obtained using a lysis and extraction buffer composed of 50 mM tris-
HCl (pH 8), 100 mM NaCl, 1% Tritón and 10mM EDTA, with the addition of 
protease inhibitor (1:10000).Protein content was determined by the Bradford 
method. 
 
Reactive oxygen species (ROS) generation: intracellular ROS study was based 
on ROS mediated conversion of non-fluorescent 2´,7´-DCFH-DA into fluorescent 
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minutes with 2´,7´-DCFH-DA (20 µM) in PBS and then irradiated (6 Gy). DCFH 
fluorescence was measured in the cell suspension by flow cytometry (Partec 
Cyflow) and analyzed (Cyflogic V.1.2.1). A group without 2´,7´-DCFH-DA was used 
as background and defined as 1. 
 
Tumor growth in vivo: C57BL/6J mice between 8-10 weeks were subcutaneously 
injected with 2.5x105 MB49 or 2x105 MB49-I into the flank. When the average 
tumor volume reached 50 mm3, animals were randomly divided into four groups of 
five-seven mice each: control, Sb, RT or Sb+RT. Sb (400 mg/kg) or equivalent 
DMSOdissolved in 0.1 mL of cell medium were administered by gavage five 
days/week, adapted from [Yan et al., 2015]. RT (18 Gy) was administered as six 
fractions of 3 Gy, being three fractions/week (Figure 5 A). RT was performed as 
previously [Prack Mc Cormick et al., 2017], mice were anesthetized with ketamine 
(70 mg/kg) and xylazine (5 mg/kg) and placed on paraffin stretchers with acrylic 
lids so that only tumors remained in the irradiation field (Figure 5 B). Tumor 
volumes were calculated as 0.4xwidth2xlength[Girit et al., 2008]. For tumor 
weights comparison, final tumor weights and tumor weights from mice 
euthanized not more than three days before the end of the assay, were 
registered. 
Mice were obtained from our Institute’s animal facility and handled in accordance 
with the international procedures for Care and Use of Laboratory Animals. 
Protocols were approved by the Institutional Review Board CICUAL, protocol 
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Tumor bearing mice survival and criteria for euthanasia: mice survival was 
carried out by the Kaplan Meier analysis based on the days of death recorded 
during the above described in vivo assays. Euthanasia was performed 
according to the ethical standards in force for national and international animal 
facilities. The ethical endpoint was determined by the presentation of at least two of 
the signs of animal discomfort or suffering listed below: decrease of more than 
10% of body weight, pilo-erection, isolation, or anorexia. 
 
Statistical analysis:In vitro results are expressed as means±SD of at least six 
replicates/group. Statistical significances were calculated by ANOVA, Student´s t-
test or Kruskal-Wallis with Dunns comparisons using 5.0 Graph-Pad-Prism. The 
Log-rank (Mantel-Cox) was used for global comparison and Gehan-Breslow-
Wilcoxon was used for comparisons between individual treatments in survival 
analysis. p<0.05 was considered significant. All experiments were repeated at 
least three times with similar results. For the graphics representing in vivo results, 
data from all experiments were combined for each cell line. 
 
RESULTS 
Silybin inhibits in vitro bladder cancer cell lines growth through different 
mechanisms 
Our results showed that Sb inhibited in vitro growth of both non-invasive and 
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105 µM for MB49 and MB49-I respectively (Figure 1 A). Clonogenic assays 
performed to evaluate single cell growth revealed that Sb 60 µM was able to inhibit 
MB49 surviving fraction while 80 µM was required for MB49-I (Figure 1 B). Despite 
that, in the invasive line we detected inhibition of the colony diameters with Sb 40 
µM (Figure 1 C-D). A cell cycle assay (Figure 1 E) showed that Sb increased the 
number of cells in S-phase in detriment of G2/M-phase in MB49-I but not in 
MB49. These results suggest that Sb-mediated MB49-I cell growth inhibition is 
related to a cell cycle detention in S-phase. On the other hand, in MB49, 48 hours 
of treatment with Sb induced apoptosis, throw caspase-3 activation followed 
by PARP cleavage. This effect was almost absent in MB49-I (Figure 1 F). 
 
Silybin enhances radiotherapy effect 
To determine whether Sb improves RT response we combined concentrations of 
Sb lower than the ID50 with RT. The cells were treated with Sb 24 hours before RT, 
andthe response to this experiment was evaluated 5 days after RT. Concentrations 
equal to or lower than 40 µM were harmless while 60 µM inhibited cell growth of 
both lines (Figure 2 A). When comparing these results with the toxicity showed in 
Figure 1 A we can see that Sb has time-dependent toxicity. Based on Sb+RT 
combinations, we calculated the radio-sensitivity factors (RSF) at 2 Gy for different 
Sb concentrations. The maximum RSF for each cell line was 1.33 and 3.08 for 
MB49 and MB49-I respectively, suggesting that invasive cells are more sensitive to 
Sb radio-sensitization. 
Then, in colony formation assays, cells were treated with RT with or without Sb 
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Sb-only or RT-only (Figure 2 B), but this response did not improve when 
treatments were combined. Improvement did not appear either when cells were 
treated with Sb 40 µM (data not shown). In MB49-I, Sb alone did not show 
inhibition (Figure 2 B), however its combination with RT did (Figure 2 C). The 
calculated DEF at 0.5 survival was 1 for MB49 and 2.1 for MB49-I, indicating that 
murine invasive cells, but not the non-invasive ones, could be radio-sensitized by 
Sb treatment.  
 
Combined treatment inhibits NF-κB activation and survivin expression 
NF-κB transcription factor is a major molecule associated with radio-resistance 
and/or tumor recurrence. Our results showed that Sb alone or combined with RT, 
inhibited NF-κB transcriptional activity in both lines. RT was not able to activate this 
factor in MB49, while a slight but significant activation of NF-κB was shown in 
MB49-I (Figure 3 A). Immunoblotting for nuclear NF-κB-p65 supported these 
results (Figure 3 B). 
Survivin is an apoptosis inhibitor that is known to be deregulated in BC and may be 
involved in RT resistance. Survivin expression was decreased after RT in MB49-I 
and after Sb+RT in both lines (Figure 3 C).  
 
Silybin increases ROS and the combined treatment inhibits pro-survival Akt 
phosphorylation 
It is known that RT increases ROS levels that have cytotoxic effect but can also 
activate pathways involved in radio-resistance as NF-κB and survival as PI3K/Akt. 
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oxidant. MB49-I cells had twice the level of ROS present in MB49 cells and Sb 
increased these levels in both cell lines. RT alone slightly modified ROS in both cell 
lines when compared with non-treated controls. ROS levels, in cells pretreated 
with Sb, were increased in response to RT in MB49 but not in MB49-I. 
However, in both cell lines, the combined treatment increased ROS as 
compared to RT alone (Figure 4 A). 
Akt expression and its activation by phosphorylation in response to RT and Sb 
were evaluated by immunoblot. RT induced an increase in Akt expression (2.5 and 
120 folds) and its phosphorylation (3.5 and 30 folds) for MB49 and MB49-I 
respectively. In MB49 cells, pAkt expression reached a peak at 30 minutes 
after RT, while in MB49-I pAkt continued increasing for 180 min (Figure 4 B-C). Sb 
reduced Akt and pAkt levels after RT in both lines. Given that MB49-I showed a 
greater increase in PI3K pathway after RT, its inhibition by Sb could be associated 
with the better response that this invasive line has compared to the non-invasive 
one. 
 
Silybin improves in vivo radiotherapy response in invasive bladder cancer 
To evaluate the radio-sensitizing effect of Sb on BC in vivo, we employed a murine 
model of tumor growth. As a measure of response we assessed tumor size, weight 
and tumor-bearing mice survival. These results were consistent with those 
observed in vitro. In MB49 tumors RT partially inhibited tumor growth (Figure 5 C-
D) and improved overall survival (Figure 5 E) without additional effects with Sb. On 
the other hand, when analyzing MB49-I tumors, RT partially inhibited tumor growth 
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improvement in MB49-I mice survival treated with Sb+RT, as compared with either 
Sb or RT alone (Figure 5 H). 
DISCUSSION 
Invasive BC is one of the most aggressive epithelial tumors and is characterized by 
a high rate of early systemic dissemination. Therefore, when it is detected, 
cystectomy is the election therapy. Taking into account the morbidity and mortality 
associated with this therapy, bladder preservation is indicated in some patients. 
One of the problems associated with the conservative therapy is the development 
of CT and RT resistances. NF-κB constitutive activation has been associated with 
tumor development and RT resistance. Since it was reported that Sb could inhibit 
NF-κB activation, in the present work we assessed the role of Sb as a radio-
sensitizer. 
Our results showed that Sb caused time-and dose-dependent inhibition of 
murine and human BC cells viability. Sb inhibited clonogenic survival of murine BC 
cells, by cell dependent mechanisms. In MB49, Sb induced apoptosis throw 
caspase-3 activation followed by PARP cleavage while in MB49-I it caused cell 
cycle arrest in S-phase. Tyagi et al reported apoptosis in transitional cell 
papilloma of the bladder (RT4) treated with Sb, throw induction of p53 
followed by caspase-2 and -3 activation and PARP cleavage [Tyagi et al., 
2006]. Apoptosis as a result of induction of ROS followed by 
ATM/p53/caspase-3 signal transduction pathway activation was recently 
reported for MB49 cells after treatment with the traditional Chinese herbal 
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associated with progression to muscle invasion [Smith et al., 2003], and 
therefore the invasive cell line MB49-I could have a less functional p53 than 
the parental MB49, being a putative hypothesis for the selective efficacy of 
Sb treatment in transitional BC cells. 
The colony formation assays showed MB49-I cells to be more resistant to 
radiation than MB49 cells, however pretreatment with Sb made MB49-I cells 
similarly sensitive to RT than MB49 cells without Sb. In agreement with our 
hypothesis Sb strongly decreased constitutive and RT-induced NF-κB activity in 
our murine BC model. Consistently, Sb was capable of partially inhibiting NF-κB-
p65 nuclear translocation in the BC cells used in this study. NF-κB-p65 RT-induced 
translocation was higher in invasive MB49-I than in non-invasive MB49 cell line, 
possibly justifying the radiosensitizing potential of Sb in the invasive one. 
Also, Sb-induced decrease of survivin expression, a target of NF-κB, was evident 
48 hours after RT. However, for future studies, further evaluations including 
other prosurvival molecules should be conducted in order to better 
understand the mechanism of radiosensitization triggered by Sb. 
Induction of ROS is one of the major mechanisms involved in electromagnetic 
radiation-induced cell death. An increase in ROS levels is capable to induce cell 
death by different mechanisms involved in DNA, membrane and protein damage 
among others[Panganiban et al., 2013]. Sb alone or combined with RT enhanced 
ROS in MB49 and MB49-I and in consequence could be responsible for the 
increased growth inhibition. Similar results were described for hepatic-cellular 
carcinoma cells treated with Sb alone[Zhang et al., 2013]. On the other hand, it is 
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we showed that Sb was able to attenuate the enhancement of PI3K/Akt pathway 
induced by RT, since either total Akt as pAkt expressions were decreased in 
irradiated cells. One of the possible mechanisms of Sb could be to diminish the 
stock of Akt to be phosphorylated, through proteasome degradation. However, we 
cannot exclude that Sb could also act directly in phosphorylation mechanisms. 
Thus, our results suggest that Sb could be considered as a radio-
sensitizercompound, enhancing oxidative stress but at the same time controlling 
survival pathways such as PI3K/Akt and NF-κB. 
Sometimes, radio-sensitizers seem effective inin vitrobut do not work under in vivo 
conditions and also have toxicity associated problems. RT significantly reduced 
tumor growth, in accordance to our in vitro results, while its combination with Sb 
only improved the response of invasive BC tumors. It is possible that a higher 
growth rate and higher activation of NF-κB and PI3K/Akt pathways in response to 
RT could make invasive tumors more sensitive to Sb treatment than non-invasive 
ones. On the other hand, it is noteworthy that even though the differences in tumor 
response between RT and Sb+RT were not statistically significant,the combined 
treatment improved invasive tumor-bearing mice overall survival with respect to 
RT. This was probably one of the most relevant results of our study.  
There are only a few studies involving the combination of Sb and RT for the 
treatment of cancer, and to our knowledge the present report is the first one 
evaluating the combination in bladder cancer. Possible combinations of Sb with 
chemoradiotherapy treatment for invasive bladder cancer [James et al., 2012] 
could be considered for future studies. Recently, Sb-based nutraceutical Legasil® 
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from lung cancer patients with poor performance status that progressed after whole 
brain radiotherapy and chemotherapy[Bosch-Barrera et al., 2016]. 
Furthermore, it has been reported that Sb could radio-sensitize prostate cancer 
cells, while protecting normal tissue from RT associated toxicity [Nambiar et al., 
2015].The authors suggest that Sb radio-sensitizing activity depends on cell 
malignancy. In our study, histologic analysis of MB49 tumors treated with Sb, 
revealed a less aggressive phenotype with a growth pattern characterized by 
pseudo-papillae with neovascularization, absent in, control tumors 
(supplementary Figure-1) as well as untreated and Sb-treated MB49-I tumors 
(supplementary Figure-2). Given that Sb protects normal tissue from RT, we 
can hypothesize that in non-invasive tumors this Sb-induced differentiation 
effect could be preventing its radio-sensitizing activity. 
Moreover, tumor progression from diploid MB49 line to MB49-I line was 
associated with an enrichment in polyploid cells, with new structural 
abnormalities and additional chromosomal imbalances [Fabris et al., 2012], 
supporting higher instability. Given that Sb targets DNA repair systems 
[Nambiar et al., 2015], and that higher instability has also been related with 
better response to sensitizers which target those repair systems [Tofilon and 
Camphausen, 2009], the differences associated with tumor progression 
could be justifying in part the fact that Sb only improves the response to RT 
in the invasive bladder cancer line both in vitro and in vivo, but not the non-
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CONCLUSION 
Our results demonstrate that Sb improves the overall survival of MB49-I tumor 
bearing mice treated with RT, and the response to RT in invasive BC MB49-I. This 
supports further studies of this therapeutic approach. 
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